Literature DB >> 18345001

TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation.

Mude Shi1, Weiwen Deng, Enguang Bi, Kairui Mao, Yongyong Ji, Guomei Lin, Xiaodong Wu, Zhiyun Tao, Zhenhu Li, Xinfen Cai, Shuhui Sun, Charlie Xiang, Bing Sun.   

Abstract

Toll-like receptor (TLR) signaling is pivotal to innate and adaptive immune responses and must be tightly controlled. The mechanisms of TLR signaling have been the focus of extensive studies. Here we report that the tripartite-motif protein TRIM30alpha, a RING protein, was induced by TLR agonists and interacted with the TAB2-TAB3-TAK1 adaptor-kinase complex involved in the activation of transcription factor NF-kappaB. TRIM30alpha promoted the degradation of TAB2 and TAB3 and inhibited NF-kappaB activation induced by TLR signaling. In vivo studies showed that transfected or transgenic mice overexpressing TRIM30alpha were more resistant to endotoxic shock. Consistent with that, in vivo 'knockdown' of TRIM30alpha mRNA by small interfering RNA impaired lipopolysaccharide-induced tolerance. Finally, expression of TRIM30alpha depended on NF-kappaB activation. Our results collectively indicate that TRIM30alpha negatively regulates TLR-mediated NF-kappaB activation by targeting degradation of TAB2 and TAB3 by a 'feedback' mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18345001     DOI: 10.1038/ni1577

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  123 in total

1.  Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7.

Authors:  Qiming Liang; Hongying Deng; Xiaojuan Li; Xianfang Wu; Qiyi Tang; Tsung-Hsien Chang; Hongzhuang Peng; Frank J Rauscher; Keiko Ozato; Fanxiu Zhu
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

Review 2.  Deciphering the complexity of Toll-like receptor signaling.

Authors:  Renato Ostuni; Ivan Zanoni; Francesca Granucci
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

Review 3.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

4.  Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition.

Authors:  Semih U Tareen; Michael Emerman
Journal:  Virology       Date:  2010-10-28       Impact factor: 3.616

5.  TRIM56 is a virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection.

Authors:  Jie Wang; Baoming Liu; Nan Wang; Young-Min Lee; Chunming Liu; Kui Li
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

6.  Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts.

Authors:  Ryusuke Yoshimi; Tsung-Hsien Chang; Hongsheng Wang; Toru Atsumi; Herbert C Morse; Keiko Ozato
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

Review 7.  Pathogen recognition and inflammatory signaling in innate immune defenses.

Authors:  Trine H Mogensen
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

8.  TRIM9 short isoform preferentially promotes DNA and RNA virus-induced production of type I interferon by recruiting GSK3β to TBK1.

Authors:  Yunfei Qin; Qingxiang Liu; Shuo Tian; Weihong Xie; Jun Cui; Rong-Fu Wang
Journal:  Cell Res       Date:  2016-02-26       Impact factor: 25.617

9.  Identification of TRIM23 as a cofactor involved in the regulation of NF-kappaB by human cytomegalovirus.

Authors:  Emma Poole; Ian Groves; Andrew MacDonald; Yin Pang; Antonio Alcami; John Sinclair
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  An expanded clade of rodent Trim5 genes.

Authors:  Semih U Tareen; Sara L Sawyer; Harmit S Malik; Michael Emerman
Journal:  Virology       Date:  2009-01-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.